DGAP-News: Expedeon AG comments on recent share price development

PRESS RELEASE
18 September 2018

/

Expedeon AG comments on recent share price development

Heidelberg, Germany and Cambridge, UK, 18 September 2018 - Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard), said today that the management is not aware of any change in the operational or strategic position of the Company which would justify the recent movement in the share price. The Management Board members Dr. Heikki Lanckriet, CEO and CSO, and David Roth, CFO, consider the price reduction unwarranted and have taken the opportunity to purchase additional shares at this morning's lower price level. Dr. Heikki Lanckriet continues to hold more than 3% of the Company's stock, increasing his holding by 12,000 shares, while David Roth increased his holding to 113,500 shares with a purchase of 30,000 shares.

Expedeon continues to pursue its successful corporate strategy and day to day business of the Company is unaffected by today's share price development. Revenue guidance for the financial year 2018 remains unchanged at EUR 13-14 million and the Company continues to expect an overall positive EBITDA for the year.

Dr. Heikki Lanckriet, CEO and CSO of Expedeon, commented: "The Management and Supervisory Board remain convinced of the success of the Expedeon business model and the creation of real value in the Company. We are proud of the achievements made during the last months and years and remain confident of this year being the most successful year in Expedeon's history."

For further information, please contact:

Expedeon AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@expedeon.com
Investor website: www.investors.expedeon.com

MC Services AG (Investor Relations and International Media Relations)
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: expedeon@mc-services.eu

About Expedeon AG: www.expedeon.com
Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###